Atrial Fibrillation | Treatment Algorithms: Claims Data Analysis | US | 2024

Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention and reoccurrence of the disease, risk assessment and prevention of stroke, ventricular rate control, and rhythm control. The choice of treatment is based on the cause and the time elapsed since the onset of symptoms. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin), rhythm control therapy (e.g., class III antiarrhythmics), and anticoagulation therapy (e.g., vitamin K antagonists, oral direct factor Xa inhibitors). This claims data analysis shows treatment patterns and brand share by line of therapy for newly diagnosed and recently treated AF patients in the United States.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AF patients?
• How have oral direct factor Xa inhibitors (i.e., apixaban, rivaroxaban, and edoxaban) been integrated into the treatment algorithm, and what is their source of business?
• What percentage of AF patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of AF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Cardinal Health, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, Pfizer, Baxter Healthcare, Validus Pharmaceuticals, Waylis Therapeutics, Bayer Healthcare.

Key drugs: Vitamin K antagonists; oral direct factor Xa inhibitors; class Ia, Ic, and III antiarrhythmics; beta blockers; calcium channel blockers; digitalis glycosides; antiplatelet agents.

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.